维普期刊资源整合服务平台（V6.5）

232篇 您的检索式：作者名="MONK BJ"

选中清除导出查看参考文献查看引证文献引用追踪共12页首页上一页第1页下一页末页 /12 跳转

	题名	作者	年代	出处	被引量
1	HPV infection and number of lifetime sexual partners are strong predictors for'natural'regression of CIN2and3显示文摘	Chan JK Monk BJ Brewer C	2003	Br J Cancer2003，89，6：	1
2	Bowel resection at the time of primary cytoreduction for epithelial ovarian cancer 显示文摘	Gillette-Cloven N Burger RA Monk BJ	2001	J Am Coll Surg2001，193，6：	1
3	Bevacizumab toxicities and their management in ovarian cancer显示文摘	Randall LM Monk BJ	2010	Gynecol Oncol2010，117，3：	1
4	Wnt signaling in ovarian tumorigenesis显示文摘	Gatcliffe TA Monk BJ Planutis K		0，，05：	1
5	Prospective Validation of Pooled Prognostic Factors in Women with Advanced Cervical Cancer Treated with Chemotherapy with/without Bevacizumab:NRG Oncology/GOG Study显示文摘	Tewari KS Sill MW Monk BJ	2015	Clin Cancer Res2015，21，24：	1
6	Prognostic factors for high-risk early-stage epithelial ovarian cancer: a Gynecologic Oncology Group study显示文摘	Chan JK Tian CQ Monk BJ	2008	Cancer2008，112，：	1
7	Phase II2 trial of four cisplatin-containing doublet combinations in stage 2VB, recurrent, or persistent cervical carcinoma: a GynecologicOncology Group study 显示文摘	Monk BJ Sill MW MeMeekin DS	2009	J Clin Oncol2009，27，28：	1
8	New strategies in advanced cervical cancer:from angiogenesis blockade to immunotherapy显示文摘	Tewari KS9 Monk BJ	2014	Clin Cancer Res2014，20，21：	1
9	Vaccines against human papillomavirus and cervical cancer:promises and challenges显示文摘	Mahdavi A Monk BJ	2005	The Oncologist2005，10，7：	1
10	Anti-angiogenesis agents in meta- static or recurrent cervical cancer显示文摘	Monk BJ Willmott Ll Sumner DA	2010	Gynecol 0ncol2010，116，2：	1
11	Age considerations when vaccinating against HPV显示文摘	Wright TC Jr Huh WK Monk BJ	2008	Gynecol Oncol2008，109，2：	1
12	Phase Ⅱ study of cisplatin and vinorelbine in squamous cell carcinoma of the cervix显示文摘	Morris M Blessing JA Monk BJ	2004	J Clin Oncol2004，22，16：	1
13	Young age as aprognostic factor in cervical cancer:results of a population-based study 显示文摘	Brewster WR D isaia PJ Monk BJ	1999	Am J obsterGynecol1999，，180：	1
14	Prognostic factors for response to cisptatin-hased chemotherapy in advanced cer- vical carcinoma: a Gynecologic Oncology Group Study显示文摘	Moore DH Tian C Monk BJ	2010	Gynecol Oncol2010，116，1：	1
15	Gemcitabine and cisplatin chemotherapy is an active combination in the treatment of platinum-resistant ovarian and peritoneal carcinoma显示文摘	Tewari D Monk BJ	2004	Invest New Drugs2004，22，4：	1
16	Survival data from a phase /I, open- label study of pazopanib or lapatinib monotherapy in patients with advanced and recurrent cervical cancer 显示文摘	Monk BJ Pandite LN	2011	Clin Oncol2011，29，36：	1
17	Laparoscopic photodynamic diagnosis of ovarian cancer using 5-Aminolevulinic acid in a rat mode显示文摘	John K Chan Y Monk BJ	2002	Gynecologic Ontology2002，87，：	1
18	Health-related quality of life outcomes associated with four cisplatin-based doublet chemotherapy regimens for stage N B recurrent or persistent cervical cancer:a Gynecologic Oncology Group study 显示文摘	Cella D Huang HQ Monk BJ	2010	Gynecol Oncol2010，119，3：	1
19	Changing the paradigm in the treatment of platinum-sensitive recurrent ovarian cancer:from platinum doublets to nonplatinum doublets and adding antiangiogenesis compounds显示文摘	Monk BJ Coleman RL	2009	Int J Gynecol Cancer2009，19，2：	1
20	Extent of disease as an indication for pelvic radiation following radical hysterectomy and bilateral pelvic lymph node dissection in the treatment of stage I B and A cervical carcinoma显示文摘	Monk BJ Cha DS Walker JL	1994	Gynecol Oncol1994，54，1：	1

返回顶部每页显示：

共12页首页上一页第1页下一页末页 /12 跳转

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

用户提示